
Saint Francis Foundation Announces Additional $1.32 Million in Community Grants
Our community partners are on the front lines in removing barriers to care, assessing social determinants of health, and improving patient access and outcomes.
'Our community partners are on the front lines in removing barriers to care, assessing social determinants of health, and improving patient access and outcomes,' said Saint Francis Foundation President Kate Smith. 'With the current political climate resulting in reductions to vital healthcare services, our community partners have sprung into action to identify gaps in maintaining their essential programming. Through the generosity and insights of our dedicated donors, the Foundation is in a unique position to help offset the impact of these federal actions.'
The following grants will support direct patient care services and capital improvements to benefit San Francisco's most vulnerable residents. The grantees are:
Larkin Street Youth Services ($325,000 for homeless youth)
As the City's largest nonprofit provider for young people experiencing homelessness and other systemic health challenges, Larkin Street Youth Services addresses the social crises and chronic mental and physical health issues for more than 1,800 young people each year. This latest Foundation funding will support Larkin Street's comprehensive shelter program (operating more than 500 beds across 16+ sites), housing, and innovative workforce development and education programs for homeless youth.
San Francisco Community Health Center ($325,000 for street medicine and trauma-informed care)
With a mission to transform lives by advancing health, wellness, and equality, San Francisco Community Health Center attends to the health and wellness of diverse communities through comprehensive medical, dental, and mental health services. This grant will sustain and strengthen SFCHC's proven street medicine model, which improves quality and health outcomes for more than 200 unhoused Tenderloin residents by delivering low-barrier, trauma-informed care directly where they live.
Hyde Street Community Services ($250,000 for intense case management)
Hyde Street Community Services provides comprehensive psychiatric, medical, substance abuse and case management services to more than 600 San Francisco residents each year. This Foundation funding will support the HSCS intense case management program, which provides direct interventions to address housing, psych medications and chronic trauma for people living in the Tenderloin.
Maitri – Compassionate Care ($225,000 for services for low-income transgender patients)
From its beginnings in the Castro as a respite for HIV-AIDS patients, Maitri has grown to provide 24x7 wrap-around services to low-income transgender and gender diverse patients who are recovering from gender-affirmation procedures. A long-time funder, the Foundation is supporting the expansion of the Maitri Affirmation Center, the leading program in San Francisco providing low-income transgender patients with access to nursing care, shelter, food, social programs, and mental health services.
Lyon-Martin Community Health Services ($150,000 for expansion of LGBTQ+ services)
For nearly 50 years, Lyon-Martin Community Health Services has been a vital lifeline for compassionate and trauma-informed medical and mental healthcare services for the LGBTQ+ community. This most recent Foundation grant will support Lyon-Martin's expansion into its new 17,000-square-foot facility that will enable it to serve 1,000 more patients annually. In 2024, Lyon-Martin completed more than 12,000 appointments and facilitated 549 gender-affirming care referrals.
Additional Foundation grants to Curry Senior Center and Sequoia Living are funding integrated mental health services for underserved older adults.
'The Saint Francis Foundation has always supported and celebrated diversity, equity, and inclusion,' said Smith. 'Today, as cuts to federal funding threaten access to care for thousands of underserved residents, we are meeting these challenges with respect, empathy and relentless persistence. Advancing the work of these community organizations has never been more urgent or important.'
About Saint Francis Foundation
As it has for almost half a century, the Saint Francis Foundation is committed to filling the gap in the delivery of high-quality, equitable and affordable healthcare in San Francisco. Building on its legacy as one of the Bay Area's most respected independent charitable foundations, the Foundation continues to fund innovative patient care and staff training programs at UCSF Health Saint Francis Hospital and provides grants to a growing number of nonprofit community partners who ensure compassionate care for patients and families beyond the hospital environment. Since its founding in 1979, the Saint Francis Foundation has contributed more than $128 million to further community healthcare access and outcomes. For more information, please visit saintfrancisfoundation.org.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time Business News
3 hours ago
- Time Business News
Next-Gen Breakthroughs Reshaping the In Vitro Diagnostics
In vitro diagnostics (IVD) refers to tests on blood, tissue, or other samples taken from the human body to detect diseases, conditions, or infections. These tests are usually used in laboratories or at the point of care for diagnosis, monitoring and treatment guidance. IVD market has increased due to increased chronic and infectious diseases, increasing demand for early and accurate diagnosis, progress in clinical technologies (eg molecular diagnosis and AI-operated equipment), expansion of elderly population, and globally more healthcare awareness. Key Growth Drivers and Opportunities Increased Chronic and Infectious Diseases: An increase in chronic and infectious diseases increases in vitro diagnostics (IVD) market, as these conditions require initial, accurate and continuous testing for effective treatment and management. Chronic diseases such as diabetes, cancer, and heart disease demand regular monitoring through blood tests, biomarkers and genetic screening, while infectious diseases such as Covid -19, HIV and tuberculosis increase the need for rapid and large -scale clinical solutions. This increased disease burden increases the demand for advanced IVD tools, which is motivated to adopt health care systems more efficient, automatic and accurate clinical technologies to improve the results of the patient. Challenges In vitro diagnostics (IVD) market faces several borders, including high costs, regulatory complications, and reimbursement challenges of advanced clinical technologies that obstruct market access. Limited infrastructure and skilled workers also prohibit adoption in low- and moderate-income countries. Additionally, concerns over the accuracy and standardization of some rapid or point-key-care tests can affect confidence in reliability and results, slowing out extensive implementation. Innovation and Expansion Launch of a New HealthTech Hub to Promote In Vitro Diagnostics In March 2025, Industry, academia, and the healthcare sector convened at the NIHR HealthTech Research Centre in In Vitro Diagnostics (HRC IVD) opening event to deliberate on the Center's goals and priorities. The HRC IVD, which is hosted by Imperial College London and Imperial College Healthcare NHS Trust and funded by the National Institute for Health and Care Research (NIHR), will aid in the advancement and uptake of diagnostics. The HRC IVD provides experience in regulatory clearances, real-world evidence creation, health economics, and overcoming adoption hurdles, with a focus on cancer, infectious and respiratory illnesses, critical care, and primary and social care. MP Biomedicals Releases Next-Generation GI Disease Diagnostic Kits In August 2024, MP Biomedicals has added new qualitative fast tests based on immunochromatography to their suite of in vitro diagnostic assays for infectious disorders. The new diagnostic kits from MP Biomedicals use state-of-the-art technology to provide reliable findings, allowing medical practitioners to quickly and accurately detect Vibrio cholerae serogroups O1 and O139, Salmonella typhi, and Helicobacter pylori. These cutting-edge diagnostic technologies have the potential to completely transform the field of gastrointestinal health diagnostics by giving medical practitioners dependable instruments for enhanced patient outcomes and early identification with previously unheard-of precision. These kits provide doctors, lab workers, and researchers useful tools that may be used in both clinical and research contexts. Inventive Sparks, Expanding Markets The key players operating the in vitro diagnostics market includes, Abbott, Qiagen, Agilent Technologies Inc., bioMerieux SA, Siemens Healthineers, Sysmex Corp., Danaher Corporation, F-Hoffman-La Roche Ltd., Charles River Laboratories, Becton Dickinson and Company, and Others. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Yahoo
4 hours ago
- Yahoo
Infectious Disease Therapies Market Projected to Reach $101 Billion by End of 2030
"As infectious diseases like HIV, hepatitis, tuberculosis, and influenza continue to challenge global health systems, new breakthroughs such as long acting injectables and monoclonal antibodies are driving better patient outcomes and fueling market growth, especially in the face of rising drug resistance." BOSTON, Aug. 14, 2025 /PRNewswire/ -- According to the latest study from BCC Research, "Global Markets for Infectious Disease Treatments" is expected to grow from $72.5 billion in 2025 to $101 billion by the end of 2030, at a compound annual growth rate (CAGR) of 6.9% during the forecast period of 2025 to 2030. This report analyzes the global market for infectious disease therapeutics, vaccines, and diagnostics, covering diseases such as HIV, influenza, hepatitis B and C, RSV, TB, HSV, malaria, rotavirus, and viral hemorrhagic fevers. It highlights market trends, challenges, and opportunities, along with insights into new products, acquisitions, collaborations, and ESG developments. The report also ranks leading companies by market share and provides detailed profiles of them. Excluded from the report are vector control strategies, symptomatic treatments, generic suppliers, and certain hospital-based diagnostic methods. This report is particularly relevant today because the COVID-19 pandemic has reshaped global priorities around infectious diseases. It exposed critical gaps in healthcare systems and underscored the urgent need for rapid diagnostics, effective treatments, and scalable vaccine platforms. In response, governments, organizations, and private companies invested in infectious disease research and infrastructure, driving innovation and global collaboration. The pandemic also highlighted the importance of early detection, surveillance, and preparedness, leading to renewed attention on emerging and neglected infectious diseases. The factors driving the market's growth include: Increasing Resistance to Drugs: Drug resistance is rising as bacteria and viruses evolve to withstand existing treatments, making infections harder to cure. This pushes pharmaceutical companies to develop new drugs and therapies, driving growth in the infectious disease treatment market. Global Efforts to Combat Infectious Diseases: Governments and international organizations are investing in public health initiatives, research, and vaccination programs to control infectious diseases. These efforts create strong support for treatment development and expand market opportunities worldwide. Technological Advances in Diagnostics and Therapeutics: Innovations like rapid testing, AI-based drug discovery, and advanced vaccines are improving how diseases are detected and treated. These technologies enhance efficiency and effectiveness, boosting demand for more effective diagnostic and therapeutic solutions. Climate Change: Changing climate patterns are expanding the reach of disease-carrying organisms, leading to the spread of infections in new regions. This increases the need for treatments in previously unaffected areas, stimulating market expansion and adaptation. Request a sample copy of the global market for infectious disease treatments report. Report Synopsis Report Metric Details Base year considered 2024 Forecast period considered 2025-2030 Base year market size $68.3 billion Market size forecast $101 billion Growth rate CAGR of 6.9% for the forecast period of 2025-2030 Segments covered Product, Disease, and Region Regions covered North America, Europe, Asia-Pacific, Middle East and Africa, and South America Countries covered U.S., Canada, Mexico, U.K., Germany, France, China, India, and Japan Market drivers • Increasing resistance to drugs. • Global efforts to combat infectious diseases. • Technological advances in diagnostics and therapeutics. • Climate change. • Increase in international travel. Interesting facts: More than 85% of hepatitis B virus infections never receive a diagnosis. Due to climate change, mosquito-borne infectious diseases are on the rise. The worldwide incidence of dengue has risen eightfold in the past 20 years. Emerging startups: Codagenix: The company develops vaccines and viral therapeutic candidates for infectious diseases. Its intranasal vaccine candidate, CoviLiv, is a live-attenuated vaccine against COVID-19. nChroma Bio: A biotechnology company advancing genetic medicines. CRMA-1001 is an epigenetic editor in development as a potential treatment for chronic hepatitis B and hepatitis D. The company plans to submit a clinical trial application in 2025. The report addresses the following questions: What are the projected size and growth rate of the Infectious disease treatments market?- The global Infectious disease treatments market was estimated at $68.3 billion in 2024. The market is projected to reach $101 billion in 2030, growing at a CAGR of 6.9% during the forecast period. Which market segments are covered in the report?- The report includes historical data and market projection on sales by product type, disease, and region. Which product type segment will be dominant through 2030?- Therapeutics is expected to have the largest share of the product type segment through the end of 2030. Which product type is showing the fastest growth?- The vaccine segment is the fastest growing product type segment. What are the key challenges and opportunities in the market?- Challenges: Pricing pressure is a significant factor restraining the growth of the infectious disease treatment market, particularly in low and middle-income countries where healthcare budgets are limited. Lack of awareness and underdiagnosis remain major barriers to the growth of the infectious disease treatment market.- Opportunities: Self-testing kits are rapidly gaining traction in the field of infectious diseases, offering individuals convenient, private, and timely diagnostic options. Market leaders include: ABBOTT ABBVIE INC. CSL DANAHER CORP. F. HOFFMANN-LA ROCHE LTD. GILEAD SCIENCES INC. GSK PLC JOHNSON & JOHNSON MERCK & CO. INC. MOLBIO DIAGNOSTICS LTD. ORASURE TECHNOLOGIES INC. PFIZER INC. SANOFI SERUM INSTITUTE OF INDIA PVT. LTD. SIEMENS HEALTHINEERS Related reports: The Global Influenza Market: This report provides a comprehensive review of the global influenza market, offering qualitative and quantitative insights. It explores the historical context of flu pandemics, current disease burden, and vaccine coverage across key regions. The market is segmented into vaccines (inactivated and live-attenuated), therapeutics, and diagnostics (rapid and conventional tests), with detailed analysis of each category. It also highlights leading products, clinical trials, new approvals, and emerging technologies. Regional demographics and growth prospects in North America, Europe, and Asia-Pacific are examined, along with strategic profiles of major companies operating in the influenza sector. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo - View original content to download multimedia: SOURCE BCC Research LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 hours ago
- Yahoo
Providence St. Joseph Hospital Foundation Establishes First-Ever Endowed Chairs to Advance Excellence in Cardiac and Cancer Care
Donor generosity provides lasting support for physician leadership, innovation and patient care in Orange County ORANGE, Calif., Aug. 13, 2025 /PRNewswire/ -- Today Providence St. Joseph Hospital Foundation has announced the establishment of its first two endowed chairs, prestigious honors that mark a significant milestone in the history of Providence St. Joseph Hospital Orange and reflect the community's deep commitment to advancing world-class care in Orange County. Endowed chairs honor physicians whose work transforms lives. Importantly, they provide sustained funding to support clinical innovation, advance research and improve outcomes. These appointments are key to attracting and supporting the brightest minds in medicine. "These endowed chairs represent a historic moment for our hospital and the communities we serve," said Amy Daugherty, chief philanthropy officer. "They are a powerful expression of gratitude, a vote of confidence in our exceptional physicians and a commitment to excellence that will benefit future generations." The newly established chairs follow. The McCulloch Family Distinguished Endowed Chair in Comprehensive Cardiac Care Ben and Laurie McCulloch made a remarkable estate gift to create the McCulloch Family Distinguished Endowed Chair in Comprehensive Cardiac Care, Providence St. Joseph Hospital Foundation's first-ever endowed chair. Cardiologist Brian Kolski, M.D., has been named as the inaugural endowed chair holder. Under the care of Dr. Kolski, Thuy Le, M.D., Jeffrey Tyler, M.D. and Katie Cornella, PA-C, Ben's life was saved many times through the years. When it became clear that a transplant wasn't a viable path forward, Ben turned once again to Dr. Kolski, who urged him to hang on. Dr. Kolski promised Ben he'd be among the first treated with the innovative new Edwards Lifesciences EVOQUE transcatheter tricuspid valve replacement system, which thanks to donor support, would soon be available at Providence St. Joseph Hospital. True to his word, Dr. Kolski, alongside Dr. Tyler and in collaboration with Dr. Le, performed one of Orange County's first EVOQUE procedures on Ben, offering hope where none existed. Today, Ben is back to living a full and active life. The McCulloch family's vision for the gift is to expand access, research and innovation in cardiac care so that more patients have options when they need them most. The David A. Margileth, M.D. Endowed Chair in Breast Cancer The David A. Margileth, M.D. Endowed Chair in Breast Cancer was funded by an anonymous donor – a two-time breast cancer survivor and longtime volunteer at the hospital, who wished to honor her retired physician, medical oncologist Dr. David Margileth. The inaugural chair holder is Hang T. Dang, D.O., director of the Breast Oncology Program and a highly regarded breast surgical oncologist. Dr. Dang will use the funds to continue advancing comprehensive breast cancer care and improve patient outcomes. The donor hopes this gift will inspire others to give back in meaningful and enduring ways. "Behind every great hospital are people who believe deeply in its mission," said Brian Helleland, chief executive, Providence St. Joseph Hospital and Orange County/High Desert service area. "The generosity of these donors honors the physicians who changed their lives and creates a ripple effect that will touch thousands more. Because of these donors and others like them, we can continue to push the boundaries of what's possible." About Providence St. Joseph Hospital Foundation Providence St. Joseph Hospital Foundation connects the philanthropic generosity of individuals and organizations with the visionary initiatives of Providence St. Joseph Hospital to achieve transformative health care. Philanthropic support enables Providence St. Joseph Hospital to keep pace with the evolving health care industry. Donations made through the Foundation support comprehensive programs, acquire leading-edge technologies and advance clinical excellence to ensure high-quality patient care. About Providence St. Joseph Hospital Providence St. Joseph Hospital in Orange, California is a nationally recognized, 483-bed, not-for-profit Catholic hospital founded in 1929 by the Sisters of St. Joseph of Orange. Fully accredited by The Joint Commission and designated as a Magnet hospital for nursing excellence, St. Joseph Hospital's reputation for clinical excellence and compassionate, family-centered care draws patients from all over the United States. St. Joseph Hospital is part of Providence, a health system serving in 52 hospitals with a comprehensive range of services across Alaska, California, Montana, New Mexico, Oregon, Texas and Washington. For more information visit: View original content to download multimedia: SOURCE Providence St. Joseph Hospital Foundation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data